Raymond James Financial
SABS icon

Raymond James Financial’s SAB Biotherapeutics SABS Stock Holding History

Raymond James Financial’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$79 – 6418
2025
Q2 		$79 Buy
+45
New +$74 ﹤0.01% 6857

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Raymond James Financial's SABS Position: Q3 2025 in Review

Raymond James Financial sold out of SAB Biotherapeutics (SABS) in Q3 2025, closing a stake of 45 shares — an estimated $79 sold.

Raymond James Financial first reported a position in SABS in Q2 2025 and held it in 1 quarter. The position peaked at $79 in Q2 2025. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2025.

  • Raymond James Financial reported no remaining SAB Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 45 SAB Biotherapeutics shares in Q3 2025, an estimated $79.
  • Raymond James Financial first reported a position in SAB Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's SAB Biotherapeutics position peaked at $79 in Q2 2025.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.